These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26107347)

  • 1. Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants.
    Yogev R; Krilov LR; Fergie JE; Weiner LB
    Pediatr Infect Dis J; 2015 Sep; 34(9):958-60. PubMed ID: 26107347
    [No Abstract]   [Full Text] [Related]  

  • 2. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].
    Sánchez Luna M; Pérez Muñuzuri A; Leante Castellanos JL; Ruiz Campillo CW; Sanz López E; Benavente Fernández I; Sánchez Redondo MD; Rite Gracia S;
    An Pediatr (Engl Ed); 2019 Nov; 91(5):348-350. PubMed ID: 31585838
    [No Abstract]   [Full Text] [Related]  

  • 3. Palivizumab prophylaxis in preterm infants.
    Tang PK
    Lancet Respir Med; 2017 Mar; 5(3):171. PubMed ID: 28219614
    [No Abstract]   [Full Text] [Related]  

  • 4. Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.
    Kool-Houweling LM; Penning-van Beest FJ; Bezemer ID; van Lingen RA; Herings RM
    Acta Paediatr; 2015 Sep; 104(9):927-32. PubMed ID: 26073782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication highlights: new recommendations for palivizumab (Synagis).
    Ridky J
    Neonatal Netw; 2014; 33(6):358-9. PubMed ID: 25551881
    [No Abstract]   [Full Text] [Related]  

  • 7. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receipt of palivizumab before birth hospitalization discharge among preterm infants in the United States.
    La Gamma EF; Kumar VR; Wadhawan R; Ye S; Sifakis F; Ycas J; Ambrose CS
    Am J Perinatol; 2015 Sep; 32(11):1017-23. PubMed ID: 25877742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA; Rao P; Brandon-Cox C
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
    Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era.
    Taylor RS
    CMAJ; 2021 Apr; 193(15):E523. PubMed ID: 33846202
    [No Abstract]   [Full Text] [Related]  

  • 20. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.